See more : MIND Technology, Inc. (MINDP) Income Statement Analysis – Financial Results
Complete financial analysis of Hemogenyx Pharmaceuticals Plc (HOPHF) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Hemogenyx Pharmaceuticals Plc, a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Indian Terrain Fashions Limited (INDTERRAIN.NS) Income Statement Analysis – Financial Results
- Bright Scholar Education Holdings Limited (BEDU) Income Statement Analysis – Financial Results
- indiePub Entertainment, Inc. (IPUB) Income Statement Analysis – Financial Results
- Kinjiro Co.,Ltd. (4013.T) Income Statement Analysis – Financial Results
- OCK Group Berhad (0172.KL) Income Statement Analysis – Financial Results
Hemogenyx Pharmaceuticals Plc (HOPHF)
About Hemogenyx Pharmaceuticals Plc
Hemogenyx Pharmaceuticals Plc, a preclinical-stage biotechnology company, focuses on the discovery, development, and commercialization of therapies and treatments for blood diseases. It is involved in developing products for bone marrow/hematopoietic stem cell (BM/HSC) transplant market, including CDX bi-specific antibody targeting relapsed/refractory acute myeloid leukaemia (R/R AML), subset of acute lymphoblastic leukaemia, and myelodysplastic syndrome conditioning bone marrow transplants to substitute traditional chemotherapy and/or radiation; HEMO-CAR-T therapy, a chimeric antigen receptor T-cells to identify and destroy human AML-derived cells in vitro and in vivo; and Human Postnatal Hematopoietic Endothelial Cells, a stem cell therapy product for BM/HSC transplants. The company was founded in 2012 and is headquartered in London, the United Kingdom.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 6.85K | 0.00 |
| Cost of Revenue | 645.68K | 2.60M | 283.65K | 350.72K | 421.82K | 348.27K | 100.48K | 66.86K | 0.00 | 0.00 |
| Gross Profit | -645.68K | -2.60M | -283.65K | -350.72K | -421.82K | -348.27K | -100.48K | -66.86K | 6.85K | 0.00 |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 100.00% | 0.00% |
| Research & Development | 90.63K | 487.10 | 50.82 | 114.41 | 28.14 | 73.50 | 18.96 | 2.00 | 0.00 | 0.00 |
| General & Administrative | 4.91M | 942.35K | 1.40M | 623.84K | 429.07K | 402.98K | 390.66K | 331.59K | 174.30K | 6.27K |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 4.22K | 33.51K | 14.63K | 19.49K | 80.40K | 3.54 | 0.00 |
| SG&A | 4.91M | 942.35K | 1.40M | 628.06K | 462.58K | 417.61K | 410.16K | 411.99K | 176.70K | 6.27K |
| Other Expenses | 1.46M | 0.00 | 0.00 | 85.24K | 213.13K | 91.36K | 101.14K | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 6.47M | 2.93M | 2.55M | 1.87M | 1.25M | 1.26M | 690.69K | 411.99K | 176.70K | 6.27K |
| Cost & Expenses | 6.47M | 5.53M | 2.83M | 2.22M | 1.67M | 1.61M | 791.17K | 411.99K | 176.70K | 6.27K |
| Interest Income | 85.34K | 10.60K | 17.96K | 3.37K | 14.19K | 4.37K | 14.50 | 14.56 | 16.25 | 0.00 |
| Interest Expense | 315.99K | 33.00 | 2.60M | 33.24K | 31.33K | 1.78K | 10.74K | 11.82K | 0.00 | 0.00 |
| Depreciation & Amortization | 225.40K | 564.07K | 126.34K | 106.75K | 94.73K | 51.81K | 33.61K | 11.87K | 169.86K | 0.00 |
| EBITDA | -5.33M | -5.44M | -2.56M | -2.08M | -1.63M | -1.63M | -837.06K | -447.15K | -0.59 | -6.27K |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -160.97% | 0.00% |
| Operating Income | -6.47M | 4.00M | -2.70M | -2.15M | -1.68M | -1.62M | -820.98K | -519.90K | -169.86K | -6.27K |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -2,481.32% | 0.00% |
| Total Other Income/Expenses | -230.65K | 10.57K | -2.41M | 55.36K | 195.99K | 27.16K | -1.49M | -11.82K | -11.02K | 0.00 |
| Income Before Tax | -6.70M | -3.99M | -5.11M | -2.10M | -1.49M | -1.52M | -2.36M | -519.90K | -180.88K | -6.27K |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -2,642.29% | 0.00% |
| Income Tax Expense | 0.00 | 361.20K | 2.41M | 20.51K | -35.00K | -43.75K | 67.10 | 215.78K | -16.25 | 0.00 |
| Net Income | -6.69M | -3.98M | -5.10M | -2.08M | -1.45M | -1.48M | -2.36M | -519.90K | -180.88K | -6.27K |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -2,642.29% | 0.00% |
| EPS | -0.01 | 0.00 | -0.01 | -0.01 | 0.00 | 0.00 | -0.01 | 0.00 | -0.01 | 0.00 |
| EPS Diluted | -0.01 | 0.00 | -0.01 | -0.01 | 0.00 | 0.00 | -0.01 | 0.00 | -0.01 | 0.00 |
| Weighted Avg Shares Out | 1.13B | 979.75M | 773.95M | 414.83M | 360.72M | 360.13M | 260.27M | 145.17M | 12.66M | 64.90M |
| Weighted Avg Shares Out (Dil) | 1.13B | 979.75M | 773.95M | 414.83M | 360.72M | 360.13M | 260.27M | 145.17M | 12.66M | 64.90M |
Hemogenyx Pharmaceuticals PLC Announces Macrophage-Directed Therapies Summit Presentation
Presentation at Macrophage-Directed Therapies Summit LONDON, UNITED KINGDOM / ACCESSWIRE / July 29, 2024 / Hemogenyx Pharmaceuticals plc ("Hemogenyx Pharmaceuticals" or the "Company")(LSE:HEMO), the clinical-stage biopharmaceutical group developing treatments for cancers and viral diseases, is pleased to announce its participation...
Hemogenyx Pharmaceuticals PLC Announces Result of Annual General Meeting
LONDON, UNITED KINGDOM / ACCESSWIRE / June 27, 2024 / Hemogenyx Pharmaceuticals plc (LSE:HEMO) is pleased to announce that, at the Annual General Meeting ("AGM") held earlier today, all resolutions were duly passed on a show of hands. The numbers...
Hemogenyx adds new trial site; making progress on multiple fronts
Hemogenyx Pharmaceuticals PLC (LSE:HEMO, OTC:HOPHF), the clinical-stage biopharmaceutical group developing treatments for cancers and viral diseases, said it has expanded its clinical trials for its lead asset, HEMO-CAR-T, adding a prestigious but unnamed US medical centre to its list of study sites. At the...
Hemogenyx Pharmaceuticals PLC Announces Operations Update
Operations Update LONDON, UNITED KINGDOM / ACCESSWIRE / June 17, 2024 / Hemogenyx Pharmaceuticals plc (LSE: HEMO), the clinical stage biopharmaceutical group developing treatments for cancers and viral diseases, is pleased to provide an update on its ongoing activities and...
Hemogenyx Pharmaceuticals PLC Announces Posting of Annual Report & Notice of AGM
Hemogenyx Pharmaceuticals plc ("Hemogenyx Pharmaceuticals" or the "Company") Posting of Annual Report & Notice of Annual General Meeting LONDON, UNITED KINGDOM / ACCESSWIRE / June 3, 2024 / Hemogenyx Pharmaceuticals plc (LSE:HEMO), the biopharmaceutical group, confirms that the Annual Report...
Hemogenyx Pharmaceuticals reflects on ‘vital year', eyes number of strategies to advance its clinical opportunities
Hemogenyx Pharmaceuticals PLC (LSE:HEMO, OTC:HOPHF) chair Marc Feldmann, in the company's final results statement, described the year as a “period was a vital one in the progression of the company.” During the year the junior biopharmaceutical group, which is developing...
Hemogenyx Pharmaceuticals reflects on ‘vital year', eyes number of strategies to advance its clinical opportunities
Hemogenyx Pharmaceuticals PLC (LSE:HEMO, OTC:HOPHF) chair Marc Feldmann, in the company's final results statement, described the year as a “period was a vital one in the progression of the company.” During the year the junior biopharmaceutical group, which is developing...
Hemogenyx Pharmaceuticals PLC Announces Final Results
THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FOR THE PURPOSES OF ARTICLE 7 OF REGULATION 2014/596/EU AS IT FORMS PART OF LAW IN THE UNITED KINGDOM BY VIRTUE OF THE EUROPEAN UNION (WITHDRAWAL) ACT 2018. UPON THE PUBLICATION OF THIS ANNOUNCEMENT, THIS...
Hemogenyx Pharmaceuticals important fund raise and CAR-T potential makes it one to watch
In a recent article, I said at least 20 micro-cap life sciences stocks were waiting to pop once interest returned to the sector. Investors can now add Hemogenyx Pharmaceuticals PLC (LSE:HEMO, OTC:HOPHF) to the watch list after it pulled off the...
Hemogenyx Pharmaceuticals important fund raise and CAR-T potential makes it one to watch
In a recent article, I said at least 20 micro-cap life sciences stocks were waiting to pop once interest returned to the sector. Investors can now add Hemogenyx Pharmaceuticals PLC (LSE:HEMO, OTC:HOPHF) to the watch list after it pulled off the...
Source: https://incomestatements.info
Category: Stock Reports